Interleukin 16 (IL-16) is a chemotactic cytokine which binds to CD4 and affects T cell activation. Here we report a novel single nucleotide polymorphism, T to C, in the promoter region of the IL-16 gene in two distinct Asian populations, Japanese and Thai. This mutation occurs at an allele frequency of approximately 22% and 18%, respectively. Although IL-16 potently suppresses replication of human immunodeficiency virus type 1 (HIV-1), we observed no significant difference in the allele frequency of this polymorphism between HIV-1-infected and non-HIV-1-infected individuals in both Asian populations. Since differential IL-16 levels have been reported to be associated with inflammatory diseases such as systemic lupus erythematosus, atopic dermatitis and allergic asthma, it would be of interest to analyze the allele frequency of this mutation in patients with these autoimmune and allergic diseases. Genes and Immunity (2000) 1, 293-294.
Introduction
Interleukin 16 (IL-16) is a chemotactic cytokine produced mainly by CD8 lymphocytes as a 67-kDa precursor protein. 1 This pro-IL-16 is subsequently processed to the mature cytokine of 13-kDa by caspase 3.
2 IL-16 inhibits the replication of macrophage-tropic and T cell line-tropic strains of HIV-1 in CD8-depleted lymphocytes. 3 In HIV-1-infected individuals, moderate levels of serum IL-16 were maintained during the asymptomatic phase and a significant drop was observed upon disease progression. 4 Recent studies also suggest that IL-16 may play a role in the mechanisms of inflammatory disease. An increased level of serum IL-16 was observed in patients with active systemic lupus erythematosus (SLE). 5 In atopic dermatitis, upregulation of IL-16 mRNA was reported to be associated with increased numbers of CD4 + cells in acute skin lesions. 6 IL-16 expression within epithelium was also reported to correlate with CD4 + cell infiltration in asthmatic patients. 7 The IL-16 gene consists of seven exons and six introns. The genomic region spanning the 408 bp upstream of the major transcription start site was shown to possess promoter activity in lymphoid cells. 8 In 
Results and Discussion
Human genomic DNA was obtained from peripheral blood mononuclear cells of 47 unrelated non-HIV-1-infected and 83 HIV-1-infected Japanese individuals. Genomic regions of 1136 nucleotides containing the first 88 nucleotides of the first exon and 1048 nucleotide of the upstream noncoding region of IL-16 were amplified using the primer pair P1: 5Ј-CTGGAAGGAAGCCTCAG CCATGTC-3Ј and P2: 5Ј-CTTGGTCTGTGGGCCGATAC-CAGGT-3Ј. Polymerase chain reaction (PCR) was run for 40 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s and extension at 72°C for 60 s. Fluorescencebased automated cycle sequencing of the PCR products was then performed by an ABI 377 by using P1, P2, and inner primers, Sense: 5Ј-CTGCCTTGTTTCTACGCTGC CCTAT-3Ј (positions −407 to −383 relative to the transcription start site), and Antisense: 5Ј-CAGCGTAGAAA-CAAGGCAGCAAAA-3Ј (positions −389 to −411). A novel single nucleotide polymorphism (T-to-C) was identified at position −295. Eighty-two unrelated non-HIV-1-infected Japanese subjects (including 47 individuals analyzed above), 143 HIV-1-infected Japanese (including 83 individuals analyzed above), 114 unrelated non-HIV-1-infected Thai, and 113 HIV-1-infected Thai were further examined for this novel polymorphism by PCR-restriction fragment length polymorphism analysis (Figure 1) .
Frequencies of T and C alleles at IL-16 −295 in Japan and Thailand are summarized in Table 1 . We observed slightly less C alleles in HIV-1-infected than in non-HIV-1-infected individuals in Japan, but this difference was not statistically significant. In Thailand, we observed virtually no difference in the frequency of the C allele between HIV-1-infected and non-HIV-1-infected individuals. These results suggest that this novel polymorphism does not exert a protective effect against HIV-1 transmission.
Although a newly-identified T-to-C polymorphism at the position −295 lies within the promoter region, further studies would be required to determine whether or not this polymorphism affects the levels of IL-16 production. It would also be interesting to analyze the allele frequency of this mutation in patients with autoimmune and allergic diseases, since evidence for involvement of IL-16 in SLE, 5 acute atopic dermatitis 6 and atopic asthma 7 have been reported. 
